- 1 comment
CYTO-CHIP shows improvement in median OS from 12.1 to 18.8 months.
Direct pelvic mass guidelines to primary care too.
Data show up to 20% higher uptake among adults, adolescents and children.
Long-term OC users had 40% reduced ovarian cancer risk, 34% reduced endometrial cancer risk.
Final data from a multicenter phase 2 trial.
Independent predictors are easy to assess.
AUA does not recommend prophylaxis beyond 24 hours.
Neonatal morbidity, mortality rates increase then plateau after 4-4.5 hours.
A paired cohort study of community-dwelling middle-aged and older adults.
Do the drugs have an antibacterial effect?
Do we have less to fear from immunosuppressants than we thought?
With expression in 82.5% of invasive breast cancers, GATA-3 has strong diagnostic potential.
Evaluation of a score based on 23 single-nucleotide polymorphisms.
Supplementation does not improve symptoms but could slow decline.
A post hoc analysis points the way to eventually settling the debate.